Galderma Group Net Income Over Time
| GALD Stock | 145.70 1.60 1.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Galderma Group Performance and Galderma Group Correlation. Galderma |
Cross Equities Net Income Analysis
Compare Galderma Group N and related stocks such as Chocoladefabriken Lindt, Chocoladefabriken Lindt, and Barry Callebaut AG Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LISP | 69.7 M | 246.5 M | 271.9 M | 303 M | 342.4 M | 380.4 M | 419.7 M | 450.7 M | 485.1 M | 509.6 M | 321.7 M | 490.5 M | 569.7 M | 671.4 M | 672.3 M | 773.1 M | 811.8 M |
| LISN | 69.7 M | 246.5 M | 271.9 M | 303 M | 342.4 M | 380.4 M | 419.7 M | 450.7 M | 485.1 M | 509.6 M | 321.7 M | 490.5 M | 569.7 M | 671.4 M | 672.3 M | 773.1 M | 811.8 M |
| BARN | 19.4 M | 142.1 M | 223.2 M | 252.4 M | 237.2 M | 217.1 M | 302.3 M | 356.1 M | 370.3 M | 316.1 M | 383.9 M | 360.7 M | 444.4 M | 189.8 M | 185.9 M | 213.7 M | 249.8 M |
| EMMN | 19.8 M | 103.5 M | 106.2 M | 104.6 M | 78.9 M | 120.2 M | 140.3 M | 161.6 M | 233.3 M | 195 M | 188.4 M | 216.7 M | 182.5 M | 186.3 M | 220.3 M | 253.3 M | 131.9 M |
| BELL | 45.3 M | 71.6 M | 75.8 M | 76.6 M | 87.7 M | 94.8 M | 100.6 M | 106.5 M | 89.3 M | 49.6 M | 118.6 M | 127.4 M | 127.8 M | 129.6 M | 123.7 M | 69.6 M | 86.9 M |
| GMI | 5 M | 8.1 M | 5.1 M | 5.1 M | 5.2 M | 5.1 M | 5.1 M | 5.8 M | 6 M | 5.6 M | 6 M | 7.2 M | 7.3 M | 6.4 M | 5.4 M | 6.2 M | 6.7 M |
| ARYN | 20.1 M | 146.3 M | 129.4 M | 135.5 M | (35.3 M) | 67 M | (907.8 M) | (470 M) | (29.2 M) | (1.1 B) | (235.8 M) | 900 K | 70 M | 129.6 M | 129.6 M | 116.6 M | 122.5 M |
| ORON | 26.9 M | 28.2 M | 27.9 M | 25.8 M | 26.5 M | 25.6 M | 28.4 M | 25.3 M | 31.8 M | 31.5 M | 21.8 M | 27.3 M | 30.2 M | 24.8 M | (35.2 M) | (31.7 M) | (30.1 M) |
| VILN | 2.9 M | 2.2 M | 3.1 M | 3.8 M | 2.7 M | 2.7 M | 2.9 M | 1.7 M | 1.4 M | 2.7 M | 636 K | 1.7 M | 1.5 M | 1.4 M | 2.7 M | 2.4 M | 2.1 M |
Galderma Group N and related stocks such as Chocoladefabriken Lindt, Chocoladefabriken Lindt, and Barry Callebaut AG Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Galderma Group N financial statement analysis. It represents the amount of money remaining after all of Galderma Group N operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Galderma Group N | GALD |
Specialization | Healthcare, Drug Manufacturers - Specialty & Generic |
| Business Address | Zhlerweg 10, Zug, |
| Exchange | SIX Swiss Exchange |
null 145.7
Additional Tools for Galderma Stock Analysis
When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.